Ousted Molina CEO: Insurers want return to pre-ACA exclusions for pre-existing conditions

Supporting the Affordable Care Act (ACA) is one possible explanation J. Mario Molina has for being unexpectedly fired as president and CEO of the managed care company his father founded, Molina Healthcare.

Molina was let go on May 2 along with brother, John, the company’s CFO. The board cited “disappointing financial performance” for the change in leadership, but Molina told POLITICO other factors may have been in play, from his outspoken criticism of ACA replacement efforts to a potential sale of the company to a larger insurer.

“I’m not aware that anyone is trying to acquire the company,” Molina said. “Certainly with John and I out of the way, it would make it easier.”

He didn’t back off from criticisms of current healthcare reform efforts in the interview, even suggesting other health plans are staying quiet because they want to see ACA regulations eliminated.

“They don’t like the health insurance tax and they would like to return to a time when they could exclude people with pre-existing conditions,” Molina said. “For them it would be a good thing to go back to the old way of doing things.”

Read the full article at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.